Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally a... скачать в хорошем качестве

Comparing two chemo regimen and chemoradiotherapy regimen as neoadjuvant treatment for locally a...

Dr Ken Kato speaks to ecancer about the JCOG1109 NExT study which is a randomised controlled phase III trial comparing two chemotherapy regimens and chemoradiotherapy regimens as neoadjuvant treatment for locally advanced oesophageal cancer. He initially, talks about the background and methodology of the study. He says that for this trial, researchers compared neoadjuvant DCF, cisplatin plus fluorouracil (CF), and CF plus radiotherapy (RT). The trial included 601 patients with stage IB-III ESCC. Their median age was 65 (range, 30-75) years, 63% had stage III (non-T4) disease, and 88% were men. Dr Kato explains the results saying that adding docetaxel to neoadjuvant cisplatin and fluorouracil prolonged overall survival for patients with locally advanced oesophagal squamous cell carcinoma (ESCC). These results suggest that neoadjuvant docetaxel, cisplatin, and fluorouracil (DCF) “represents a new standard treatment for locally advanced ESCC”. He concludes by discussing the impact of these results of the future treatment of oesophageal cancer. Sign up to ecancer for free to receive tailored email alerts for more videos like this. ecancer.org/account/register.php